🇺🇸 FDA
Patent

US 8921071

Targeting poly-gamma-glutamic acid to treat Staphylococcus epidermidis and related infections

granted A61KA61K2039/6037A61K2039/6056

Quick answer

US patent 8921071 (Targeting poly-gamma-glutamic acid to treat Staphylococcus epidermidis and related infections) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Dec 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2039/6037, A61K2039/6056, A61K2039/6081, A61K39/085